^
    1d
    Multidisciplinary consensus recommendations for the management of IDH-mutant grade 2 gliomas in Spain: a Delphi study. (PubMed, Clin Transl Oncol)
    This work delivers multidisciplinary consensus recommendations to standardize care in IDH-mutant grade 2 gliomas, integrating advances in molecular diagnostics, imaging, and therapeutics. It also identifies key knowledge gaps and clinical uncertainties, underscoring the critical need for ongoing research and expert collaboration to continually refine personalized management approaches and improve patient outcomes.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Voranigo (vorasidenib)
    1d
    Effects of short- and long-term mutant IDH1 inhibition on radiosensitivity across genetically diverse patient-derived IDH1-mutant glioma cells. (PubMed, Neurooncol Adv)
    We investigated the effects of short-term (5 days) and long-term (≥5 weeks) exposure to the IDH1 inhibitor AGI-5198 on radiation-induced cytotoxicity...Effects were comparable to short-term treatment, while radiation responses varied by genetic context. No deleterious interaction between IDHi and IR was observed in endogenous IDH-mutant cells except for MGG18 Tet+ supporting integration of IDHi with radiotherapy in IDH mutant gliomas.
    Journal • BRCA Biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    BRCA2 mutation • IDH1 mutation • IDH1 R132
    |
    AGI-5198
    5d
    A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=18, Recruiting, Memorial Sloan Kettering Cancer Center | N=36 --> 18
    Enrollment change
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation • FLT3 mutation
    |
    Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)
    8d
    Breast cancer tumor immune microenvironment landscape identifies prognostic risk genes and potential drugs. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
    Furthermore, fourteen candidate drugs targeting this network were predicted, and structural analogs of Lumacaftor and Ivosidenib showed promising docking affinities to CD1C and CXCR3, respectively. These findings provide preliminary insights into TIM-associated prognostic pathways and suggest candidate compounds for further investigation in BRCA.
    Journal
    |
    BRCA (Breast cancer early onset) • CD69 (CD69 Molecule) • CD40LG (CD40 ligand) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CD1C (CD1c Molecule)
    |
    Tibsovo (ivosidenib)
    12d
    Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies (clinicaltrials.gov)
    P4, N=16, Recruiting, Rigel Pharmaceuticals
    New P4 trial
    |
    Rezlidhia (olutasidenib)
    14d
    AB-218-IIT-201: A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (clinicaltrials.gov)
    P1, N=14, Completed, Melbourne Health | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Dec 2024 --> Mar 2025 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    safusidenib (DS-1001)
    15d
    A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment (clinicaltrials.gov)
    P1, N=25, Recruiting, Servier Bio-Innovation LLC
    New P1 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132
    |
    Tibsovo (ivosidenib)
    15d
    The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1. (PubMed, J Clin Invest)
    Gemcitabine-based chemotherapy is the standard treatment regime for advanced intrahepatic cholangiocarcinoma (iCCA), but the frequent presence of chemoresistance limits its efficacy. The low level of Mg2+, an ion that competitively hinders binding of ivosidenib on wtIDH1, in iCCA tumor microenvironment contributed to the expanded therapeutic window of ivosidenib in patients with iCCA. Our work revealed the potency of combining targeting IDH1 and chemotherapy against wtIDH1 iCCA and other tumors.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH wild-type
    |
    gemcitabine • Tibsovo (ivosidenib)
    20d
    VANGUARD: Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Huashan Hospital
    New trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Voranigo (vorasidenib)
    20d
    Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Timothy Pardee
    New P2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)
    20d
    CL1-95032-005: Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Institut de Recherches Internationales Servier | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler)
    |
    IDH1 R132
    |
    Keytruda (pembrolizumab) • Voranigo (vorasidenib)
    22d
    MIVONU: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, French Innovative Leukemia Organisation
    New P2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 R132
    |
    Tibsovo (ivosidenib) • Onureg (azacitidine oral)